Skip to content
Assyro AI
US FDA source recordAL · Approval Letter

METRO I.V. IN PLASTIC CONTAINER — FDA Approval Letter (NDA 018900)

Issued to B BRAUN. Application is approved as submitted.

Application

NDA 505b1 • 018900

Product

METRO I.V. IN PLASTIC CONTAINER

Company

B BRAUN

Stage

Final Decision

Assyro regulatory brief

Free

What did FDA decide for METRO I.V. IN PLASTIC CONTAINER?

Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.

Verify in source

Source facts

FDA issued an approval letter for METRO I.V. IN PLASTIC CONTAINER on 2026-04-27. The source metadata identifies NDA 018900 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

Key details in this letter

  • 1FDA action: approval.
  • 2Application: NDA 018900.
  • 3Submission: supplement.
  • 4Sponsor: B BRAUN.

Suggested next step

Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.

Open the document workspace

Built from structured FDA metadata and deterministic source-text signals. Topic matches are navigation aids, not legal or regulatory conclusions. Verify material decisions against the original FDA document.

FDAPDFUpdated Jul 30, 2026

FDA source document

Read the full FDA approval letter (PDF)

Loading document viewer…

Common questions about the METRO I.V. IN PLASTIC CONTAINER approval letter

Is METRO I.V. IN PLASTIC CONTAINER FDA approved?

This letter documents an FDA approval action: FDA approved NDA 018900 for METRO I.V. IN PLASTIC CONTAINER, sponsored by B BRAUN, on April 27, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.

What is NDA 018900?

NDA 018900 is the application under which FDA issued this approval letter for METRO I.V. IN PLASTIC CONTAINER to B BRAUN. The letter is dated April 27, 2026.

What happens after an FDA approval letter?

The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.